Phase II trial of the farnesyltransferase inhibitor tipifarnib plus fulvestrant in hormone receptor-positive metastatic breast cancer: New York Cancer Consortium Trial P6205

Annals of Oncology

Volumn 20, Issue 4, 2009, Pages 642-647

  Li, T ^a   Christos, P J ^b   Sparano, J A ^a   Hershman, D L ^c   Hoschander, S ^a   O'Brien, K ^b   Wright, J J ^d   Vahdat, L T ^c  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c New York Presbyterian Hospital Columbia University Medical Center   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Farnesyl transferase inhibitor; Fulvestrant; Metastatic breast cancer; Postmenopausal; Selective estrogen receptor downregulator; Tipifarnib

Indexed keywords

AROMATASE INHIBITOR; FULVESTRANT; HORMONE RECEPTOR; PROTEIN FARNESYLTRANSFERASE INHIBITOR; TAMOXIFEN; TIPIFARNIB;

ADULT; AGED; AGITATION; ANEMIA; ANOREXIA; ANXIETY; ARTICLE; ATAXIA; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CARDIOVASCULAR DISEASE; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONFUSION; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG POTENTIATION; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; FATIGUE; FEMALE; GASTROINTESTINAL SYMPTOM; HEART MUSCLE ISCHEMIA; HEMATOLOGIC DISEASE; HUMAN; HYPERGLYCEMIA; HYPOCALCEMIA; HYPOKALEMIA; INFECTION; INSOMNIA; KIDNEY DISEASE; LUNG DISEASE; METABOLIC DISORDER; METASTASIS; MULTIPLE CYCLE TREATMENT; MYOCARDITIS; NAUSEA; NEUROLOGIC DISEASE; NEUROPATHY; NEUTROPENIA; PERICARDIAL EFFUSION; PHASE 2 CLINICAL TRIAL; PNEUMONIA; POSTMENOPAUSE; PRIORITY JOURNAL; SIDE EFFECT; SINGLE DRUG DOSE; SKIN DISEASE; THROMBOSIS; TREATMENT PLANNING; TREMOR;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; ESTRADIOL; FARNESYLTRANSTRANSFERASE; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM METASTASIS; QUINOLONES; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TREATMENT OUTCOME;

EID: 63549098589     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdn689     Document Type: Article

References (27)

1. Muss HB. Endocrine therapy for advanced breast cancer: A review. Breast Cancer Res Treat 1992; 21: 15-26.
2. Hortobagyi GN. Treatment of breast cancer. N Engl J Med 1998; 339: 974-984.
3. Pritchard KI. Endocrine therapy for breast cancer. Oncology (Williston Park) 2000; 14: 483-492; discussion 493, 497-488.
4. Howell A, Robertson JF, Quaresma Albano J et al. Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment. J Clin Oncol 2002; 20: 3396-3403.
5. Osborne CK, Pippen J, Jones SE et al. Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: Results of a North American trial. J Clin Oncol 2002; 20: 3386-3395.
6. Howell A, Robertson JF, Abram P et al. Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: A multinational, double-blind, randomized trial. J Clin Oncol 2004; 22: 1605-1613.
7. Gradishar WJ, Sahmoud T. Current and future perspectives on fulvestrant. Clin Breast Cancer 2005; 6 (Suppl 1): S23-S29.
8. Robertson JF, Come SE, Jones SE et al. Endocrine treatment options for advanced breast cancer - the role of fulvestrant. Eur J Cancer 2005; 41: 346-356.
9. Howell A, Pippen J, Elledge RM et al. Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma: A prospectively planned combined survival analysis of two multicenter trials. Cancer 2005; 104: 236-239.
10. Robertson JF, Osborne CK, Howell A et al. Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women: a prospective combined analysis of two multicenter trials. Cancer 2003; 98: 229-238.
11. Mauriac L, Pippen JE, Quaresma Albano J et al. Fulvestrant (Faslodex) versus anastrozole for the second-line treatment of advanced breast cancer in subgroups of postmenopausal women with visceral and non-visceral metastases: Combined results from two multicentre trials. Eur J Cancer 2003; 39: 1228-1233.
12. Dodwell D, Vergote I. A comparison of fulvestrant and the third-generation aromatase inhibitors in the second-line treatment of postmenopausal women with advanced breast cancer. Cancer Treat Rev 2005; 31: 274-282.
13. Ingle JN, Suman VJ, Rowland KM et al. Fulvestrant in women with advanced breast cancer after progression on prior aromatase inhibitor therapy: North Central Cancer Treatment Group Trial N0032. J Clin Oncol 2006; 24: 1052-1056.
14. Perey L, Paridaens R, Hawle H et al. Clinical benefit of fulvestrant in postmenopausal women with advanced breast cancer and primary or acquired resistance to aromatase inhibitors: Final results of phase II Swiss Group for Clinical Cancer Research Trial (SAKK 21/00). Ann Oncol 2007; 18: 64-90.
15. Chia S, Gradishar W, Mauriac L et al. Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: Results from EFECT. J Clin Oncol 2008; 26: 1664-1670.
16. Yue W, Fan P, Wang J et al. Mechanisms of acquired resistance to endocrine therapy in hormone-dependent breast cancer cells. J Steroid Biochem Mol Biol 2007; 106: 102-110.
17. Berstein LM, Zheng H, Yue W et al. New approaches to the understanding of tamoxifen action and resistance. Endocr Relat Cancer 2003; 10: 267-277.
18. Kelland LR, Smith V, Valenti M et al. Preclinical antitumor activity and pharmacodynamic studies with the farnesyl protein transferase inhibitor R115777 in human breast cancer. Clin Cancer Res 2001; 7: 3544-3550.
19. Li T, Sparano JA. Inhibiting Ras signaling in the therapy of breast cancer. Clin Breast Cancer 2003; 3: 405-416; discussion 417-420.
20. Johnston SR, Hickish T, Ellis P et al. Phase II study of the efficacy and tolerability of two dosing regimens of the farnesyl transferase inhibitor, R115777, in advanced breast cancer. J Clin Oncol 2003; 21: 2492-2499.
21. Fan M, Yan PS, Hartman-Frey C et al. Diverse gene expression and DNA methylation profiles correlate with differential adaptation of breast cancer cells to the antiestrogens tamoxifen and fulvestrant. Cancer Res 2006; 66: 11954-11966.
22. Johnston SR, Head J, Pancholi S et al. Integration of signal transduction inhibitors with endocrine therapy: An approach to overcoming hormone resistance in breast cancer. Clin Cancer Res 2003; 9: 524S-532S.
23. Martin LA, Head JE, Pancholi S et al. The farnesyltransferase inhibitor R115777 (tipifarnib) in combination with tamoxifen acts synergistically to inhibit MCF-7 breast cancer cell proliferation and cell cycle progression in vitro and in vivo. Mol Cancer Ther 2007; 6: 2458-2467.
24. Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205-216.
25. Johnston SR, Semiglazov VF, Manikhas GM et al. A phase II, randomized, blinded study of the farnesyltransferase inhibitor tipifarnib combined with letrozole in the treatment of advanced breast cancer after antiestrogen therapy San Antonio Breast Cancer Symposium: 2005; (Abstr 5087).
26. Johnston SR, Semiglazov VF, Manikhas GM et al. A phase II, randomized, blinded study of the farnesyltransferase inhibitor tipifarnib combined with letrozole in the treatment of advanced breast cancer after antiestrogen therapy. Breast Cancer Res Treat 2008; 110: 327-335.
27. Lara PN Jr, Law LY, Wright JJ et al. Intermittent dosing of the farnesyl transferase inhibitor tipifarnib (R115777) in advanced malignant solid tumors: A phase I California Cancer Consortium Trial. Anticancer Drugs 2005; 16: 317-321.